HomeCompareMBGYY vs ABBV

MBGYY vs ABBV: Dividend Comparison 2026

MBGYY yields 7.79% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MBGYY wins by $87066.48M in total portfolio value
10 years
MBGYY
MBGYY
● Live price
7.79%
Share price
$15.31
Annual div
$1.19
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$87066.58M
Annual income
$84,972,104,824.51
Full MBGYY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MBGYY vs ABBV

📍 MBGYY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMBGYYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MBGYY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MBGYY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MBGYY
Annual income on $10K today (after 15% tax)
$662.46/yr
After 10yr DRIP, annual income (after tax)
$72,226,289,100.83/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MBGYY beats the other by $72,226,268,044.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MBGYY + ABBV for your $10,000?

MBGYY: 50%ABBV: 50%
100% ABBV50/50100% MBGYY
Portfolio after 10yr
$43533.34M
Annual income
$42,486,064,798.13/yr
Blended yield
97.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MBGYY
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
1.3
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MBGYY buys
0
ABBV buys
0
No recent congressional trades found for MBGYY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMBGYYABBV
Forward yield7.79%3.06%
Annual dividend / share$1.19$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$87066.58M$102.3K
Annual income after 10y$84,972,104,824.51$24,771.77
Total dividends collected$86923.42M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: MBGYY vs ABBV ($10,000, DRIP)

YearMBGYY PortfolioMBGYY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,259$1,558.72$11,550$430.00+$709.00MBGYY
2$16,688$3,571.57$13,472$627.96+$3.2KMBGYY
3$26,945$9,088.14$15,906$926.08+$11.0KMBGYY
4$56,258$27,427.15$19,071$1,382.55+$37.2KMBGYY
5$167,234$107,037.83$23,302$2,095.81+$143.9KMBGYY
6$773,675$594,734.97$29,150$3,237.93+$744.5KMBGYY
7$5,970,685$5,142,852.38$37,536$5,121.41+$5.93MMBGYY
8$80,573,569$74,184,936.12$50,079$8,338.38+$80.52MMBGYY
9$1,957,457,605$1,871,243,885.92$69,753$14,065.80+$1957.39MMBGYY
10$87,066,584,462$84,972,104,824.51$102,337$24,771.77+$87066.48MMBGYY

MBGYY vs ABBV: Complete Analysis 2026

MBGYYStock

Mercedes-Benz Group AG operates as an automotive company in Germany and internationally. The company develops, manufactures, and sells passenger cars comprising premium and luxury vehicles of the Mercedes-Benz brand, including the Mercedes-AMG, G-Class, Mercedes-Maybach, and Mercedes-EQ brands, as well as small cars under the smart brand; ecosystem of Mercedes-Benz under the Mercedes me brand; and vans under the Mercedes-Benz and Freightliner brands, as well as related spare parts and accessories. It also provides financing and leasing packages for end-customers and dealers; automotive insurance brokerage and banking services; car subscription and car rental, and fleet management, as well as digital services for charging and payment; and mobility services. The company was formerly known as Daimler AG and changed its name to Mercedes-Benz Group AG in February 2022. Mercedes-Benz Group AG was founded in 1886 and is headquartered in Stuttgart, Germany.

Full MBGYY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MBGYY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MBGYY vs SCHDMBGYY vs JEPIMBGYY vs OMBGYY vs KOMBGYY vs MAINMBGYY vs JNJMBGYY vs MRKMBGYY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.